3 High-Growth Stocks That Are Just Getting Started

In This Article:

Most businesses posting rapid expansion right now will not be able to maintain that level of growth over time. On the other hand, there will be standouts -- the rare companies with the right makeup and competitive advantages to capitalize on market trends and repeatedly take their businesses to the next level.

Having even a few of these companies working in your favor over the long term can be a life-changing event. To help put readers on to some high-growth stocks that still have big potential, we asked three Motley Fool investors to profile a top growth investment. Read on to see why they identified Codexis (NASDAQ: CDXS), Activision Blizzard (NASDAQ: ATVI), and Control4 Corporation (NASDAQ: CTRL) as top stocks for growth-seeking investors.

A paper cutout of a rocket at the top of an ascending chart line.
A paper cutout of a rocket at the top of an ascending chart line.

Image source: Getty Images.

The emerging opportunity of enzyme engineering

Maxx Chatsko (Codexis): While the technology platform isn't grabbing headlines today, the long-term opportunity presented by enzyme engineering shouldn't be overlooked by investors. Codexis is a leader in designing biocatalysts, or molecules created from living organisms that increase the efficiency and lower costs of industrial and chemical manufacturing processes. It's quietly becoming big business for the well-positioned biotech.

In 2017, Codexis grew product revenue 75% from the prior year to nearly $27 million. It raked in enough collaboration revenue to push total sales to $50 million for the first time in company history. The growth stock is just getting started.

Full-year 2018 guidance calls for $60 million to $63 million in revenue at a gross margin of 46.5%. While product revenue is expected to be flat for the year -- which was a bit of a disappointment -- investors can chalk it up to growing pains for a young technology platform expanding its reach.

Historically, Codexis has only sold its enzymes to improve the efficiency of small-molecule pharmaceutical manufacturing processes. But in the last two years or so, it has expanded into food ingredient manufacturing and DNA sequencing applications. In the near future, it will enter into industrial applications, perhaps in metalworking or leatherworking. It will just take a little time to build a foothold in new industries to enable sustainable growth, so year-over-year numbers could be choppy.

The company isn't stopping there. While the core business is focused on selling enzymes for improving manufacturing processes, Codexis is beginning partnered clinical trials for an engineered enzyme that could potentially treat the rare disease phenylketonuria (PKU). The fact that it's not entirely dependent on a biopharma pipeline, and has an incredibly profitable industrial enzyme business, significantly de-risks clinical trials for shareholders.